Filters

Clinical trials

Compound NCT Number Status Phases Study title Conditions URL
Pacritinib NCT02765724 Completed Phase 1 Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects Myelofibrosis https://ClinicalTrials.gov/show/NCT02765724
Pacritinib NCT02803762 Completed Phase 1 Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib Healthy https://ClinicalTrials.gov/show/NCT02803762
Pacritinib NCT02532010 Terminated Phase 2 Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML Acute Myeloid Leukemia (AML) https://ClinicalTrials.gov/show/NCT02532010
Pacritinib NCT02807051 Completed Phase 1 To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects Drug Interaction Study https://ClinicalTrials.gov/show/NCT02807051
Pacritinib NCT02807116 Completed Phase 1 Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects Healthy Subjects https://ClinicalTrials.gov/show/NCT02807116
Pacritinib NCT02055781 Terminated Phase 3 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT02055781
Pacritinib NCT03645824 Recruiting Phase 2 Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) Myelofibrosis https://ClinicalTrials.gov/show/NCT03645824
Pacritinib NCT03165734 Recruiting Phase 2|Phase 3 A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT03165734
Pacritinib NCT01773187 Terminated Phase 3 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT01773187
Pacritinib NCT03601819 Recruiting Phase 1 Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Chronic Lymphocytic Leukemia|Lymphoproliferative Disorders|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03601819
Pacritinib NCT02677948 Withdrawn Phase 1|Phase 2 Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Chronic Lymphocytic Leukemia|Lymphoma, Small Lymphocytic https://ClinicalTrials.gov/show/NCT02677948
Pacritinib NCT02277093 Terminated Phase 2 Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer Colorectal Cancer https://ClinicalTrials.gov/show/NCT02277093
Pacritinib NCT02410551 Terminated Phase 2 Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) Myeloproliferative Diseases https://ClinicalTrials.gov/show/NCT02410551
Pacritinib NCT02564536 Withdrawn Phase 1 Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia|Atypical Chronic Myeloid Leukemia|Myeloproliferative Neoplasm|Myelodysplastic Syndromes|Myelofibrosis https://ClinicalTrials.gov/show/NCT02564536
Pacritinib NCT02469415 Terminated Phase 2 Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Leukemia https://ClinicalTrials.gov/show/NCT02469415
Pacritinib NCT02807077 Completed Phase 1 PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects Myelofibrosis https://ClinicalTrials.gov/show/NCT02807077
Pacritinib NCT02808455 Completed Phase 1 Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects Healthy Subjects https://ClinicalTrials.gov/show/NCT02808455
Pacritinib NCT02891603 Recruiting Phase 1|Phase 2 A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression Graft Vs Host Disease|GVHD https://ClinicalTrials.gov/show/NCT02891603
Pacritinib NCT02584777 Withdrawn Phase 2 A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis Primary Myelofibrosis https://ClinicalTrials.gov/show/NCT02584777
Pacritinib NCT02323607 Completed Phase 1 Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02323607
Pacritinib NCT02342353 Terminated Phase 1 Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer|Carcinoma, Non-Small-Cell Lung https://ClinicalTrials.gov/show/NCT02342353
Pacritinib NCT02823171 Completed Phase 1 To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects Healthy https://ClinicalTrials.gov/show/NCT02823171
Pacritinib NCT02807207 Completed Phase 1 To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects Healthy Subjects https://ClinicalTrials.gov/show/NCT02807207